Urinary Bladder OveractivePhase 3SYNERGY IINCT02045862
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
A Phase 3 study testing Solifenacin succinate and Mirabegron in people with Urinary Bladder Overactive and Overactive Bladder, run by Astellas Pharma Europe B.V. at 251 sites in 32 countries.
Trial summary
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence
- What is being tested?
- Solifenacin succinate and Mirabegron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,829 participants
- Where
- 251 sitesin 32 countries
- Study dates
- 17 Mar 2014to 8 Sep 2016
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Main Inclusion at Screening (Visit 1):
- Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012 had been completed. In that case the subject had to have symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for at least 3 months);
- Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
- Main Inclusion at Randomization (Visit 2):
- Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during the last 7 days of the micturition diary period (incontinence episode should not be counted as a micturition).
- Subject had experienced at least 3 incontinence episodes during the last 7 days of the micturition diary period.
- Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient Perception of Intensity of Urgency Scale [PPIUS]) per 24-hour period during the 7-day micturition diary period.
Who cannot join
- Main Exclusion at Screening (Visit 1):
- Subject had clinically significant bladder outflow obstruction at risk of urinary retention;
- Subject had significant PVR volume (> 150 mL);
- Subject had significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor;
- Subject has an indwelling catheter or practices intermittent self-catheterization;
- Subject had evidence of a UTI (urine culture containing > 100,000 cfu/mL), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
Show all 10Show fewer
- Subject had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;
- Main Exclusion at Randomization (Visit 2):
- Subject had evidence of a urinary tract infection (UTI) (urine culture containing > 100,000 cfu/mL) as assessed in the Screening visit (V1) samples. The subject could be rescreened after successful treatment of the UTI (confirmed by a dipstick negative for nitrite).
- Subject had an average total daily urine volume > 3000 mL as recorded in the micturition diary period.
Trial locations and contacts
251 sites in 32 countries.
251 sites in 32 countries
United States75 sites
Site US10011
Albuquerque, New Mexico, 87102
Site US10015
Albuquerque, New Mexico, 87109
Site US10037
Alpharetta, Georgia, 30005
Site US10122
Anaheim, California, 92801
Site US10008
Bala-Cynwyd, Pennsylvania, 19004
Site US10110
Billings, Montana, 59102
Site US10282
Boston, Massachusetts, 02131
Site US10060
Bradenton, Florida, 34208
Site US10013
Burien, Washington, 98166
Site US10104
Chandler, Arizona, 85224
Site US10166
Charleston, South Carolina, 29425
Site US10050
Cleveland, Ohio, 44122
Site US10076
Concord, North Carolina, 28025
Site US10065
Corpus Christi, Texas, 78414
Site US10002
Englewood, New Jersey, 07631
Site US10026
Garden City, New York, 11530
Site US10558
Hanover, Maryland, 21076
Site US10082
Hawaiian Gardens, California, 90716
Site US10097
Hialeah, Florida, 33012
Site US10148
Hialeah, Florida, 33016
Site US10153
Hialeah, Florida, 33016
Site US10085
Houston, Texas, 77058
Site US10219
Houston, Texas, 77094
Site US10093
Houston, Texas, 77099
Site US10090
Hurst, Texas, 76054
Site US10091
Jupiter, Florida, 33458
Site US10006
Kingsport, Tennessee, 37660
Site US10040
Kingston, New York, 12401
Site US10088
Lake Charles, Louisiana, 70601
Site US10047
Lawrenceville, New Jersey, 08648
Site US10553
Lincoln, Nebraska, 68510
Site US10132
Los Angeles, California, 90017
Site US10133
Los Angeles, California, 90036
Site US10541
Medford, Oregon, 97504
Site US10154
Missoula, Montana, 59801
Site US10049
Mobile, Alabama, 36608
Site US10112
Mobile, Alabama, 36608
Site US10004
Mountlake Terrace, Washington, 98043
Site US10079
Mt. Pleasant, South Carolina, 29464
Site US10150
New Port Richey, Florida, 34652
Site US10168
New York, New York, 10065
Site US10126
Newburgh, New York, 12550
Site US10109
Oklahoma City, Oklahoma, 73112
Site US10124
Orlando, Florida, 32803
Site US10134
Orlando, Florida, 32806
Site US10149
Paramount, California, 90723
Site US10009
Pembroke Pines, Florida, 33027
Site US10017
Philadelphia, Pennsylvania, 19114
Site US10021
Phoenix, Arizona, 85051
Site US10167
Pittsburgh, Pennsylvania, 15213
Site US10250
Pittsburgh, Pennsylvania, 15236
Site US10248
Pittsburgh, Pennsylvania, 15243
Site US10554
Plantation, Florida, 33317
Site US10028
Poughkeepsie, New York, 12601
Site US10129
Raleigh, North Carolina, 27609
Site US10127
Roswell, Georgia, 30076
Site US10105
San Antonio, Texas, 78229
Site US10111
San Antonio, Texas, 78229
Site US10003
San Diego, California, 92120
Site US10120
Sandy Springs, Georgia, 30328
Site US10155
Seattle, Washington, 98105
Site US10025
Shreveport, Louisiana, 71106
Site US10023
Simpsonville, South Carolina, 29681
Site US10101
Summerville, South Carolina, 29485
Site US10106
Tarzana, California, 91356
Site US10063
Uniontown, Pennsylvania, 15401
Site US10595
Valley Village, California, 91607
Site US10083
Virginia Beach, Virginia, 23462
Site US10067
Wadsworth, Ohio, 44281
Site US10135
Walla Walla, Washington, 99362
Site US10114
Watertown, Massachusetts, 02472
Site US10012
West Reading, Pennsylvania, 19611
Site US10053
Wheat Ridge, Colorado, 80033
Site US10078
Wichita, Kansas, 67205
Site US10062
Winston-Salem, North Carolina, 27103
South Korea20 sites
Site KR82014
Bucheon-si, Gyunggido, 420-767
Site KR82006
Busan, 602-715
Site KR82016
Busan, 602-739
Site KR82005
Daegu, 705-717
Site KR82029
Daegu, 705-718
Site KR82019
Daejeon, 301-721
Site KR82023
Incheon, 405760
Site KR82010
Jeonju, Jeollabuk-do South Korea, 561-712
Site KR82012
Seoul, Gyunggido, 143-729
Site KR82003
Seoul, 05505
Site KR82021
Seoul, 100-380
Site KR82020
Seoul, 110-744
Site KR82030
Seoul, 120-752
Site KR82013
Seoul, 134-701
Site KR82017
Seoul, 134-872
Site KR82002
Seoul, 135-710
Site KR82008
Seoul, 135-720
Site KR82015
Seoul, 136-075
Site KR82001
Seoul, 137-701
Site KR82004
Suwon, Gyeonggi-do, 443-721
Canada15 sites
Site CA15001
Barrie, Ontario, L4M 7G1
Site CA15006
Brampton, Ontario, L6T 4S5
Site CA15003
Brantford, Ontario, N3S 6T6
Site CA15026
Drummondville, Quebec, J2B 7T1
Site CA15035
Edmonton, Alberta, T5G 0B7
Site CA15007
Kitchener, Ontario, N2N 2B9
Site CA15039
Lévis, Quebec, G6W 5M6
Site CA15020
Montreal, Quebec, H4N 3C5
Site CA15040
Montreal, H2R 1V6
Site CA15025
Québec, Quebec, G1S 2L6
Site CA15008
Saint John, New Brunswick, E2L 3J8
Site CA15027
Sherbrooke, Quebec, J1H 1Z1
Site CA15013
Toronto, Ontario, M4N 3M5
Site CA15004
Toronto, Ontario, M4S 1Y2
Site CA15033
Vancouver, British Columbia, V5Z 4E1
Germany12 sites
Site DE49008
Bad Ems, 56130
Site DE49031
Bergisch Gladbach, Northwest, 51427
Site DE49032
Duisburg, North Rhine-Westphalia, 47179
Site DE49002
Duisburg, 47051
Site DE49003
Eisleben Lutherstadt, Saxony-Anhalt, 06295
Site DE49010
Ganderkesee, 27777
Site DE49011
Halle, 06132
Site DE49013
Leipzig, Saxony, 04105
Site DE49034
Munich, Bavaria, 81377
Site DE49001
Neustadt in Sachsen, 01844
Site DE49026
Rostock, 18107
Site DE49014
Sangerhausen, 06526
Poland12 sites
Site PL48018
Bialystok, 15-351
Site PL48013
Chorzów, 41-500
Site PL48014
Gdynia, 81-384
Site PL48004
Lodz, 90-302
Site PL48010
Lublin, 20-632
Site PL48011
Mysłowice, 41-400
Site PL48016
Opole, 45-086
Site PL48005
Piaseczno, 05-500
Site PL48012
Warsaw, 00-909
Site PL48003
Warsaw, 02-507
Site PL48001
Warsaw, 02-929
Site PL48019
Wroclaw, 50-088
Australia11 sites
Site AU61022
Brisbane, Queensland, 4152
Site AU61005
Broadmeadow, New South Wales, 2292
Site AU61015
Daw Park, South Australia, 5041
Site AU61025
Footscray, Victoria, 3011
Site AU61010
Nambour, Queensland, 4560
Site AU61002
Parkville, Victoria, 3052
Site AU61004
Perth, Western Australia, 6009
Site AU61007
Randwick, New South Wales, 2031
Site AU61021
Randwick, New South Wales, 2031
Site AU61019
Sherwood, Queensland, 4075
Site AU61011
Wollongong, New South Wales, 2522
Czechia11 sites
Site CZ42015
Brno, 602 00
Site CZ42003
Hradec Králové, 500 02
Site CZ42001
Hradec Králové, 50005
Site CZ42010
Olomouc, 772 00
Site CZ42014
Ostrava, 700 30
Site CZ42005
Pilsen, 32600
Site CZ42008
Prague, 12808
Site CZ42007
Prague, 140 00
Site CZ42013
Sternberk, 78501
Site CZ42009
Uherské Hradiště, 686 08
Site CZ42006
Ústí nad Labem, 40001
Lithuania8 sites
Site LT37008
Kaunas, 47144
Site LT37004
Kaunas, 50009
Site LT37011
Kaunas, LT49449
Site LT37012
Klaipėda, LT-92288
Site LT37010
Vilnius, 10207
Site LT37003
Vilnius, LT-01118
Site LT37007
Vilnius, LT-08661
Site LT37009
Vilnius, LT-09108
Slovakia8 sites
Site SK42105
Bratislava, 82101
Site SK42107
Košice, 04001
Site SK42101
Košice, 04013
Site SK42103
Nitra, 949 01
Site SK42108
Poprad, 05801
Site SK42104
Prešov, 080 01
Site SK42102
Trenčín, 91101
Site SK42106
Trenčín, 91101
Russia7 sites
Site RU70015
Kazan', 420097
Site RU70023
Penza, 440026
Site RU70019
Saint Petersburg, 194354
Site RU70002
Saint Petersburg, 197089
Site RU70022
Saint Petersburg, 198103
Site RU70014
Saint Petersburg, 199178
Site RU70018
Ufa, 450096
Ukraine7 sites
Site UA38002
Cherenigiv, 14034
Site UA38015
Chernivtsi, 58002
Site UA38013
Dnipro, 49005
Site UA38007
Kiev, 02232
Site UA38003
Kyiv, 02660
Site UA38010
Kyiv, 04053
Site UA38008
Zaporizhzhya, 69600
Hungary6 sites
Site HU36003
Csongrád, Csongrád megye, 6640
Site HU36007
Kecskemét, Bacs-Kiskun Megye, 6000
Site HU36005
Pécs, Baranya, 7621
Site HU36013
Sopron, Győr-Moson-Sopron, 9400
Site HU36001
Szentes, Csongrád megye, 6600
Site HU36012
Veszprém, Veszprém megye, 8200
Romania6 sites
Site RO40004
Bucharest, 042122
Site RO40001
Bucharest, 50659
Site RO40005
Bucharest, 50659
Site RO40014
Cluj-Napoca, Cluj, 400046
Site RO40010
Sibiu, 550245
Site RO40002
Timișoara, 300736
Sweden6 sites
Site SE46007
Borås, 506 30
Site SE46005
Malmö, 211 52
Site SE46016
Stockholm, 111 57
Site SE46012
Stockholm, 141 86
Site SE46003
Stockholm, 182 88
Site SE46009
Uppsala, 753 19
South Africa5 sites
Site ZA27001
Centurion, Gauteng, 0157
Site ZA27006
Durban, KwaZulu-Natal, 4001
Site ZA27013
Meyerspark, Pretoria, 0184
Site ZA27007
Paarl, Western Cape, 7646
Site ZA27002
Roodepoort, Gauteng, 1709
Bulgaria4 sites
Site BG35908
Plovdiv, 4003
Site BG35902
Rousse, 7000
Site BG35905
Sofia, 1431
Site BG35903
Sofia, 1606
Italy4 sites
Site IT39022
Ancona, 60126
Site IT39007
Avellino, 83100
Site IT39001
Latina, 04100
Site IT39020
Milan, 20100
Netherlands4 sites
Site NL31002
Amsterdam, 1105 AZ
Site NL31006
Enschede, NL, 7513ER
Site NL31005
Nijmegen, 6532 SZ
Site NL31010
Sneek, 8601 ZK
New Zealand4 sites
Site NZ64001
Christchurch, Canterbury, 8013
Site NZ64002
Nelson, 7010
Site NZ64003
Tauranga, 3140
Site NZ64006
Whangarei, 0112
Spain4 sites
Site ES34004
Madrid, 28031
Site ES34015
Madrid, 28044
Site ES34009
Madrid, 28046
Site ES34002
Valencia, 46026
Belgium3 sites
Site BE32004
Ghent, 9000
Site BE32014
Roeselare, 8800
Site BE32012
Sint-Truiden, 3800
Latvia3 sites
Site LV37102
Liepāja, LV-3401
Site LV37103
Olaine, LV-2114
Site LV37105
Riga, LV-1002
Norway3 sites
Site NO47007
Ålesund, 6003
Site NO47006
Hamar, 2317
Site NO47008
Lierskogen, 3420
United Kingdom3 sites
Site GB44006
Plymouth, PL6 8DH
Site GB44001
Sheffield, South Yorkshire, S10 2JF
Site GB44009
Watford, WD25 7NL
Singapore2 sites
Site SG65002
Singapore, 169608
Site SG65003
Singapore, 229899
About this study
Official title: A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Being tested
- Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
- Keywords
- Solifenacin Succinate, Mirabegron, Urinary Incontinence, Combination Therapy, Urgency, Nocturia, Overactive Bladder
- Medical subject headings
- Urinary Bladder, Overactive, Urinary Incontinence, Nocturia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Solifenacin succinateDrug
Also called Vesicare, Vesitrim, YM905, Vesikur
Participants received solifenacin 5 mg orally once a day at the same time each day.
MirabegronDrug
Also called Myrbetriq, YM178, Betmiga, Betanis
Participants received mirabegron 50 mg orally once a day at the same time each day.
Placebo to match solifenacinDrug
Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Placebo to match mirabegronDrug
Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
| Study group | Role | What they receive |
|---|---|---|
| Mirabegron 50 mg | Active comparator | Participants received mirabegron 50 mg once a day for 52 weeks. Receives: Drug: Mirabegron; Drug: Placebo to match solifenacin |
| Solifenacin 5 mg | Active comparator | Participants received solifenacin 5 mg once a day for 52 weeks. Receives: Drug: Solifenacin succinate; Drug: Placebo to match mirabegron |
| Solifenacin 5 mg + Mirabegron 50 mg | Experimental | Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks. Receives: Drug: Solifenacin succinate; Drug: Mirabegron |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) observed after taking the first dose of double-blind treatment until 14 days after taking the last dose of double-blind treatment for non-serious AEs and until 30 days after taking the last dose of double-blind treatment for serious adverse events (SAEs). This included abnormal laboratory tests, vital signs or electrocardiogram data that were defined as AEs if the abnormality induced clinical signs or symptoms, required active intervention, interruption or discontinuation of study drug or was clinically significant in the investigator's opinion. The severity of each AE was defined according to the following: Mild (No disruption of normal daily activities); Moderate (Affected normal daily activities) and Severe (Inability to perform daily activities).
Measured: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to the baseline and week 52 clinic visits.
Measured: Baseline and Week 52
Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
A micturition was defined as any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant in a micturition diary for 7-days before the baseline and week 52 clinic visits.
Measured: Baseline and Week 52
Secondary outcomes (55)
Change From Baseline to EoT in Mean Volume Voided Per Micturition
The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.
Measured: Baseline and Week 52
Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.
Measured: Baseline and Week 52
Change From Baseline to EoT in the Patient's Assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.
Measured: Baseline and Week 52
Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to the baseline and prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The number of incontinence episodes was the total number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The number of incontinence episodes was the total number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Incontinence-Free Days During the 7-Day Micturition Diary Period Prior to Each Visit
The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period prior to each visit with no incontinence episodes recorded.
Measured: Months 1, 3, 6, 9, 12
Number of Incontinence-Free Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit
The number of incontinence-free days with < 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with < 8 micturitions per day.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceeded by urgency. The number of urgency incontinence episodes was the total number of urgency incontinence episodes recorded by the participant during the 7-day micturition diary period prior to each visit.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the total number of urgency incontinence episodes recorded by the participant during the 7-day micturition diary period prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Micturitions Per 24 Hours
A micturition was defined as any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant in a micturition diary for 7-days before the baseline and prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit (at Months 1, 3, 6, 9, 12 and EoT)
The number of days with < 8 micturitions was the number of valid diary days during the 7-day micturition diary period with with less than 8 micturitions per day.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to EoT in Corrected Micturition Frequency
Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline. Corrected micturition frequency was calculated as the baseline mean volume voided per micturition multiplied by the baseline mean number of micturitions per 24 hours divided by the mean volume voided per micturition at EoT.
Measured: Baseline and Month 12
Change From Baseline to Months 3, 6 and 12 in Mean Volume Voided Per Micturition
The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period prior to each visit.
Measured: Baseline and Months 3, 6, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. An urgency episode was defined as any micturition or incontinence episode recorded by the participant in the micturition diary for 7 days prior to each visit as 3 or 4 on the Patient Perception of Intensity of Urgency Scale (PPIUS), where 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could delay voiding a short while; 3 = Severe urgency, could not delay voiding; 4 = Urge incontinence, leaked before arriving to the toilet.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The mean number of nocturia episodes was calculated from data recorded by the participant in the micturition diary for 7 days prior to each visit."
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Nocturia Episodes Reported During the 7-Day Micturition Diary Period Prior to Each Visit
A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode during the 7-day micturition diary period prior to each visit.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Nocturia Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode during the 7-day micturition diary period prior to each visit
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Pads Used Per 24 Hours
The mean number of pads used per 24 hours was calculated from data recorded by the participant in the micturition diary for 7 days prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
The number of pads used was the number of times a participant recorded a new pad used during the 7-day micturition diary period prior to each visit.
Measured: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
The number of pads used was the number of times a participant recorded a new pad used during the 7-day micturition diary period prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in the OAB-q Symptom Bother Score
The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQoL): Total Score
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Coping
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Concern
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Sleep
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consisted of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each time was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQL Subscale Score: Social
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in the Patient's Assessment of TS-VAS
The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Patient Perception of Bladder Condition (PPBC)
The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants in Each Category of Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Month 12 and EoT
The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).
Measured: Month 12
Percentage of Participants in Each Category of PGIC Scale: Impression in General Health at Month 12 and EoT
The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).
Measured: Month 12
Number of Participants With Change From Baseline to EoT in European Quality of Llife in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility
The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Measured: Baseline and 12 Months
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care
The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Measured: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities
The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Measured: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort
The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and had 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Measured: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression
The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and had 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Measured: Baseline and Month 12
Change From Baseline to Months 6, 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.
Measured: Baseline and Months 6,12
Change From Baseline to Months 6, 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.
Measured: Baseline and Months 6, 12
Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Overall Work Impairment
The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes arre expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.
Measured: Baseline and Months 6, 12
Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Activity Impairment
The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.
Measured: Baseline and Months 6, 12
Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The percentage of participants with no incontinence episodes recorded during the last 3 days of the 7-day micturition diary is reported.
Measured: Months 1, 3, 6, 9, 12
Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Months 1, 3, 6, 9, 12 and EoT
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQoL Total Score at Months 1, 3, 6, 9, 12 and EoT
The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The percentage of participants with no incontinence episodes recorded during the 7-day micturition diary is reported.
Measured: Months 1, 3, 6, 9, 12
Percentage of Participants With Micturition Frequency Normalization at Months 1, 3, 6, 9, 12 and EoT
The percentage of participants with micturition frequency normalization was defined as participants who had ≥ 8 micturitions/24 hours at baseline and < 8 micturitions/24 hours postbaseline at months 1, 3, 6, 9, 12 and EoT.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q Symptom Bother Scale and ≥1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The symptom bother portion of the OAB-q consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q HRQL Total Score and ≥ 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The HRQoL portion of the OAB-q consists of 25 HRQoL items comprising 4 HRQoL subscales, each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Measured: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Postvoid Residual (PVR) Volume
PVR volume was assessed by ultrasonography or a bladder scanner.
Measured: Baseline and Months 1, 3, 6, 9, 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2014 (estimated)
- Study start17 Mar 2014
- Primary completion8 Sep 2016
- Study completion8 Sep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Urinary Bladder OveractiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,829 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Europe B.V.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Astellas Pharma Europe B.V.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02045862
- Sponsor's protocol ID
- 178-CL-102
- Other IDs
- 2012-005736-29
- Acronym
- SYNERGY II
- Status last verified
- Oct 2024
- First submitted
- 23 Jan 2014
- Last updated
- 31 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Publications
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.
PubMed 29866467
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder
- ClinicalTrials.gov ID
- NCT02045862
- Acronym / sponsor ID
- SYNERGY II / 178-CL-102
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Keywords
- Solifenacin Succinate, Mirabegron, Urinary Incontinence, Combination Therapy, Urgency, Nocturia, Overactive Bladder
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,829 participants (actual)
- Lead sponsor
- Astellas Pharma Europe B.V.Industry (pharma, biotech, devices)
- Study start
- 17 Mar 2014 (actual)
- Primary completion
- 8 Sep 2016 (actual)
- Study completion
- 8 Sep 2016 (actual)
- First posted
- 27 Jan 2014 (estimated)
- Results
- Posted 6 Jun 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Mirabegron 50 mg | Active comparator | Drug: Mirabegron, Drug: Placebo to match solifenacinParticipants received mirabegron 50 mg once a day for 52 weeks. |
| Solifenacin 5 mg | Active comparator | Drug: Solifenacin succinate, Drug: Placebo to match mirabegronParticipants received solifenacin 5 mg once a day for 52 weeks. |
| Solifenacin 5 mg + Mirabegron 50 mg | Experimental | Drug: Solifenacin succinate, Drug: MirabegronParticipants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012 had been completed. In that case the subject had to have symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for at least 3 months);
- Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
- Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during the last 7 days of the micturition diary period (incontinence episode should not be counted as a micturition).
- Subject had experienced at least 3 incontinence episodes during the last 7 days of the micturition diary period.
- Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient Perception of Intensity of Urgency Scale [PPIUS]) per 24-hour period during the 7-day micturition diary period.
Key exclusion criteria (10 listed)
- Subject had clinically significant bladder outflow obstruction at risk of urinary retention;
- Subject had significant PVR volume (> 150 mL);
- Subject had significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor;
- Subject has an indwelling catheter or practices intermittent self-catheterization;
- Subject had evidence of a UTI (urine culture containing > 100,000 cfu/mL), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Solifenacin succinateAlso: Vesicare, Vesitrim, YM905, VesikurParticipants received solifenacin 5 mg orally once a day at the same time each day. | Drug | Solifenacin 5 mg, Solifenacin 5 mg + Mirabegron 50 mg |
| MirabegronAlso: Myrbetriq, YM178, Betmiga, BetanisParticipants received mirabegron 50 mg orally once a day at the same time each day. | Drug | Mirabegron 50 mg, Solifenacin 5 mg + Mirabegron 50 mg |
| Placebo to match solifenacinParticipants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study. | Drug | Mirabegron 50 mg |
| Placebo to match mirabegronParticipants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study. | Drug | Solifenacin 5 mg |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)
A TEAE was defined as an adverse event (AE) observed after taking the first dose of double-blind treatment until 14 days after taking the last dose of double-blind treatment for non-serious AEs and until 30 days after taking the last dose of double-blind treatment for serious adverse events (SAEs). This included abnormal laboratory tests, vital signs or electrocardiogram data that were defined as AEs if the abnormality induced clinical signs or symptoms, required active intervention, interruption or discontinuation of study drug or was clinically significant in the investigator's opinion. The severity of each AE was defined according to the following: Mild (No disruption of normal daily activities); Moderate (Affected normal daily activities) and Severe (Inability to perform daily activities).
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
Time frame: Baseline and Week 52
An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to the baseline and week 52 clinic visits.
Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
Time frame: Baseline and Week 52
A micturition was defined as any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant in a micturition diary for 7-days before the baseline and week 52 clinic visits.
55 secondary outcomes
Change From Baseline to EoT in Mean Volume Voided Per Micturition
Time frame: Baseline and Week 52
Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
Time frame: Baseline and Week 52
Change From Baseline to EoT in the Patient's Assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
Time frame: Baseline and Week 52
Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Incontinence-Free Days During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Number of Incontinence-Free Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Micturitions Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit (at Months 1, 3, 6, 9, 12 and EoT)
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to EoT in Corrected Micturition Frequency
Time frame: Baseline and Month 12
Change From Baseline to Months 3, 6 and 12 in Mean Volume Voided Per Micturition
Time frame: Baseline and Months 3, 6, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Nocturia Episodes Reported During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Nocturia Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Pads Used Per 24 Hours
Time frame: Baseline and Months 1, 3, 6, 9, 12
Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in the OAB-q Symptom Bother Score
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQoL): Total Score
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Coping
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Concern
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Sleep
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQL Subscale Score: Social
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9 and 12 in the Patient's Assessment of TS-VAS
Time frame: Baseline and Months 1, 3, 6, 9, 12
Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Patient Perception of Bladder Condition (PPBC)
Time frame: Baseline and Months 1, 3, 6, 9, 12
Percentage of Participants in Each Category of Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Month 12 and EoT
Time frame: Month 12
Percentage of Participants in Each Category of PGIC Scale: Impression in General Health at Month 12 and EoT
Time frame: Month 12
Number of Participants With Change From Baseline to EoT in European Quality of Llife in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility
Time frame: Baseline and 12 Months
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care
Time frame: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities
Time frame: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort
Time frame: Baseline and Month 12
Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression
Time frame: Baseline and Month 12
Change From Baseline to Months 6, 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
Time frame: Baseline and Months 6,12
Change From Baseline to Months 6, 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
Time frame: Baseline and Months 6, 12
Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Overall Work Impairment
Time frame: Baseline and Months 6, 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 29866467Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.
- Individual participant dataSharing planned: Yes. Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Related trials for Urinary Bladder Overactive
RecruitingObservational study
Tensi+ European Post-Market Clinical Follow-Up
Overactive Bladder
Not yet recruiting
Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke
Stroke, Neurogenic Overactive Bladder
Not yet recruiting
Parasacral TENS Project
Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
Active, not recruiting
INTIBIA Pivotal Study
Urinary Incontinence, Urge, Urinary Bladder, Overactive
Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Overactive Bladder, Urge Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Astellas Pharma Europe B.V.
251 sites in 32 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Solifenacin succinate and Mirabegron in people with Urinary Bladder Overactive and Overactive Bladder, run by Astellas Pharma Europe B.V. at 251 sites in 32 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 251 sites in United States, South Korea, Canada, Germany, Poland and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (time frame: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02045862, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.